Nexalin Technology Initiates Pivotal HALO™ Clarity Insomnia Trial, Q2 2026 Enrollment Expected
NXL sits 44% above its 52-week low of $0.33.
Summary
Nexalin Technology announced it has entered into agreements to advance its pivotal clinical trial for the HALO™ Clarity device, targeting moderate-to-severe insomnia, with patient enrollment expected to begin in Q2 2026. This 160-participant, triple-blinded, sham-controlled study is designed to support a planned De Novo FDA submission, which, if granted, would establish a new product category. This news provides a concrete update on the company's FDA strategy, following a recent announcement of general progress and the publication of a peer-reviewed pilot study. For a micro-cap company currently facing a going concern warning and Nasdaq delisting threat, this significant step towards regulatory approval for a key product is highly material, offering a potential path to commercialization and improved financial stability. Traders will closely monitor updates on site activation and patient enrollment as the trial progresses.
At the time of this announcement, NXL was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8M. The 52-week trading range was $0.33 to $2.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.